Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.

Ann Hematol 2018 Aug 3;97(8):1417-1425. Epub 2018 Apr 3.

Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

The treatment approaches for Waldenstrom macroglobulinemia (WM) are largely based upon information from single-arm phase II trials, without comparative data. We compared the efficacy of two commonly used regimens in routine practice (bendamustine-rituximab (BR) and dexamethasone, rituximab plus cyclophosphamide (DRC)) and evaluated their activity with respect to the patients' MYD88 mutation status. Of 160 consecutive patients, 60 received BR (43 with relapsed/refractory WM) and 100 received DRC (50 had relapsed/refractory WM). In the treatment-naïve setting, overall response rate (ORR) was 93% with BR versus 96% with DRC (p = 0.55). Two-year progression-free survival (PFS) with BR and DRC was 88 and 61%, respectively (p = 0.07). In salvage setting, ORR was 95% with BR versus 87% with DRC, p = 0.45; median PFS with BR was 58 versus 32 months with DRC (2-year PFS was 66 versus 53%; p = 0.08). Median disease-specific survival was not reached with BR versus 166 months with DRC (p = 0.51). The time-to-event endpoints and depth of response were independent of the MYD88 mutation status. Grade ≥ 3 adverse events of both regimens were comparable. A trend for longer PFS was observed with BR although the regimens have comparable toxicities. The activity of BR and DRC appears to be unaffected by patients' MYD88 mutation status.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3311-zDOI Listing
August 2018
33 Reads

Publication Analysis

Top Keywords

myd88 mutation
12
mutation status
12
drc
9
rituximab cyclophosphamide
8
cyclophosphamide drc
8
pfs versus
8
patients' myd88
8
regimens comparable
8
dexamethasone rituximab
8
versus
6
versus 96%
4
96% drc
4
93% versus
4
orr 93%
4
drc p = 055
4
grade ≥ 3
4
status grade
4
pfs
4
survival pfs
4
progression-free survival
4

References

(Supplied by CrossRef)
Article in Semin Oncol
RG Owen et al.
Semin Oncol 2003
Article in N Engl J Med
SP Treon et al.
N Engl J Med 2012
Article in J Clin Oncol
MA Dimopoulos et al.
J Clin Oncol 1994
Article in Br J Haematol
RA Kyle et al.
Br J Haematol 2000
Article in Blood Rev
P Kapoor et al.
Blood Rev 2015
Article in Drugs
F Cameron et al.
Drugs 2014
Article in N Engl J Med
SP Treon et al.
N Engl J Med 2015
Article in N Engl J Med
SP Treon et al.
N Engl J Med 2015
Article in J Oncol Pract
TD Shanafelt et al.
J Oncol Pract 2015
Article in J Clin Oncol
MA Dimopoulos et al.
J Clin Oncol 2007
Article in Lancet
MJ Rummel et al.
Lancet 2013

Similar Publications